Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 164

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 9B
Chunk 164
---
 for these activities
are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the
financial statements as prepaid or accrued research and development expense, as the case may be. Total research and development costs
for the years ended December 31, 2024, and 2023 were $492,660 and $954,793, respectively.

    F-8

JUPITER
NEUROSCIENCES, INC.

NOTES
TO FINANCIAL STATEMENTS

December
31, 2024 and 2023

Note
2 – Significant Accounting Policies, continued

Income
Taxes

The
Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis
of our assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws
on deferred taxes, if any, applied during the years in which temporary differences are expected to be settled, is reflected in the financial
statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence,
it is more likely than not that some, or all, of the deferred tax assets will not be realized. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. As of December 31, 2024 and 2023, the Company concluded that a full valuation allowance is necessary for the net deferred tax assets. The Company had
no material amounts recorded for uncertain tax positions, interest or penalties in the accompanying financial statements. The Company
is subject to taxation in the U.S. Our tax years for 2021 and forward are subject to examination by tax authorities. The Company is not
currently under examination by any tax authority.

Loss
Per Share of Common Stock

Basic
loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common
stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of
securities, such as convertible preferred stock, convertible notes payable, warrants, stock options, and unvested restricted stock, which
would result in the issuance of incremental shares of common stock, as calculated using the treasury method. In computing the basic and
diluted net loss per share applicable to common stockholders, the